文献速递产科母胎医学

妊娠35-37周子痫前期的筛查

Screening for pre-eclampsia at 35-37 weeks' gestation.
PubMed 文献 · Ultrasound Obstet Gynecol · 2018-08-27

这项前瞻性观察研究纳入13350例单胎妊娠,在35+0至36+6周联合母体因素与MAP、PlGF、sFlt-1等标志物筛查子痫前期。以1/20为风险界值时,联合母体因素、MAP、PlGF和sFlt-1对子痫前期的检出率为70%;筛查性能因种族来源而异。

要点

  • 在35-37周,联合母体因素、MAP、PlGF和sFlt-1筛查子痫前期,风险界值1/20时检出率为70%。
  • 加用UtA-PI未改善筛查性能。
  • 筛查性能因种族来源而异。

核心结论

  • 在妊娠35-37周通过母体因素和生物标志物筛查可识别高比例晚发型子痫前期妊娠。
  • 筛查性能取决于孕妇的种族来源。

研究设计与样本

  • 前瞻性观察研究,纳入13350例单胎妊娠,于35+0至36+6周进行超声检查。
  • 采用贝叶斯定理,将基于母体特征和病史获得的子痫前期分娩孕周先验分布,与各生物标志物中位数倍数(MoM)值的不同组合相结合,得出个体化子痫前期分娩风险。

主要发现

  • 研究人群13350例妊娠中,272例(2.0%)后续发生子痫前期。
  • 发生子痫前期的妊娠中,MAP、UtA-PI和sFlt-1的MoM值升高,PlGF MoM值降低。
  • 风险界值1/20时,高风险组约占总人群10%;仅用母体因素筛查时该组包含28%的子痫前期病例,加用MAP后检出率升至53%,加用MAP和PlGF后升至67%,加用MAP、PlGF和sFlt-1后升至70%。
  • 加用UtA-PI未改善筛查性能。
  • 采用母体因素、MAP、PlGF和sFlt-1联合筛查且风险界值1/20时,白人女性的检出率和筛查阳性率分别为66%和9.5%,非裔加勒比裔女性分别为88%和18%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the performance of screening for pre-eclampsia (PE) at 35-37 weeks' gestation by maternal factors and combinations of mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), serum placental growth factor (PlGF) and serum soluble fms-like tyrosine kinase-1 (sFlt-1). METHODS: This was a prospective observational study in women with singleton pregnancy attending for an ultrasound scan at 35 + 0 to 36 + 6 weeks as part of routine pregnancy care. Bayes' theorem was used to combine the prior distribution of gestational age at delivery with PE, obtained from maternal characteristics and medical history, with various combinations of biomarker multiples of the median (MoM) values to derive the patient-specific risks of delivery with PE. The performance of such screening was estimated. RESULTS: The study population of 13 350 pregnancies included 272 (2.0%) that subsequently developed PE. In pregnancies that developed PE, the MoM values of MAP, UtA-PI and sFlt-1 were increased and PlGF MoM was decreased. At a risk cut-off of 1 in 20, the proportion of the population stratified into high risk was about 10% of the total, and the proportion of cases of PE contained within this high-risk group was 28% with screening by maternal factors alone; the detection rate increased to 53% with the addition of MAP, 67% with the addition of MAP and PlGF and 70% with the addition of MAP, PlGF and sFlt-1. The performance of screening was not improved by the addition of UtA-PI. The performance of screening depended on the racial origin of the women; in screening by a combination of maternal factors, MAP, PlGF and sFlt-1 and use of the risk cut-off of 1 in 20, the detection rate and screen-positive rate were 66% and 9.5%, respectively, for Caucasian women and 88% and 18% for those of Afro-Caribbean racial origin. CONCLUSION: Screening by maternal factors and biomarkers at 35-37 weeks' gestation can identify a high proportion of pregnancies that develop late PE. The performance of screening depends on the racial origin of the women. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Panaitescu A, Ciobanu A, Syngelaki A, et al. Screening for pre-eclampsia at 35-37 weeks' gestation. Ultrasound Obstet Gynecol. 2018. PMID: 29896778. doi:10.1002/uog.19111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。